XBIO — Xenetic Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1534525 ·
Last close
$1.61
Market Cap
$3.77M
52W High
$4.94
52W Low
$1.43
ADV30
21,893
Next earnings
—
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 725,257 — -1,739,152 -1,695,478 6,317,611 5,809,635 1,904,046
Jun 2026 660,601 — -971,690 -929,695 6,967,998 6,471,766 894,977
Mar 2026 806,923 — -502,117 -456,382 7,908,991 7,347,255 958,239
Dec 2025 766,296 — -623,027 -579,076 8,363,847 7,883,632 968,025

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,312,795
Investing CF
—
Financing CF
—
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.39
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-201,261,408
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-2,641,568
Pretax Income TTM
$-2,475,093
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,260,777
EBITDA
—
Free Cash Flow
$-1,174,761
Enterprise Value
$-2,582,085
Total Cash
$6,471,766
Total Debt
$0
Shares Out
2,343,181
Trailing EPS
$-1.15
Book Value
$3.23
ROE
-47.0%
ROA
-26.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,976,411 -2,834,582 -2,680,860 8,363,847 968,025 7,395,822 -2,286,651
Dec 2024 2,500,284 -4,204,428 -3,960,275 6,901,443 894,263 6,007,180 -2,817,478
Dec 2023 2,539,986 -4,515,715 -4,134,578 10,605,226 809,585 9,795,641 -4,114,219
Dec 2022 1,706,925 -6,717,908 -6,552,353 14,700,000 1,073,156 13,647,134 -4,646,765

TTM Snapshot

Revenues TTM
$3,260,777
NetIncome TTM
$-2,475,093
OpCashFlow TTM
—
Assets (Latest)
$6,967,998
Forward EPS
$-0.66

Peers — same industry

TickerNameMarket CapLastDaily %
SXTC China SXT Pharmaceuticals, Inc. $3.78M $2.86 —
NCNA NuCana plc $3.70M $0.89 —
AZTR Azitra, Inc. $3.68M $0.61 —
TRAW Traws Pharma, Inc. $3.59M $0.23 —
IMNN Imunon, Inc. $3.97M $0.61 —

News headlines (Yahoo Finance, 1h cache)

Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
2026-11-13 13:30 · Yahoo
Xenetic Biosciences: Q3 Earnings Snapshot
2026-11-12 22:08 · Yahoo
Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
2026-11-04 14:20 · Yahoo
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells f
2026-10-15 12:46 · Yahoo
Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake
2026-09-16 14:30 · Yahoo
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
2026-09-16 14:28 · Yahoo
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
2026-09-16 11:00 · Yahoo
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
2026-04-22 13:00 · Yahoo
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
2026-05-13 12:05 · Yahoo
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination
2026-06-04 12:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.